Log in to search using one of your social media accounts:

 

A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma

A systematic review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. The criteria for inclusion of the trials were established before the review. A search of Medline, Embase, and the Cochrane library databases was conducted to identify phase II or III randomized controlled trials (RCTs), reported from January 1, 1994 to May 29, 2016. Relevant conference abstracts, citation lists from the included articles, published guidelines, and on-going clinical trial databases were also searched.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Source Type: research

Related Links:

This article looks at the symptoms, causes, and treatment options for the disease.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Abstract Background: Patients hospitalized with hematologic malignancy are particularly vulnerable to infection. The impact of reported beta-lactam (BL) allergy in this population remains unknown. Objective: To define the impact of reported BL-only allergy (BLOA) label on clinical outcomes compared to those with no BL allergy (NBLA) in hematologic malignancy inpatients requiring systemic antibiotics. Methods: Retrospective cohort study of adult inpatients with hematologic malignancy admitted at two tertiary care hospitals 2010-2015. The primary outcome was hospital length of stay (LOS) after first antibi...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Infect Dis Source Type: research
Conclusion This study did not support associations between night-shift work and hematological cancers.byTalibov M, Pukkala E, Martinsen JI, Tryggvadottir L, Weiderpass E, Hansen J. doi:10.5271/sjweh.3704
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Tags: Original article Source Type: research
Conclusion This study did not support associations between night-shift work and hematological cancers. PMID: 29323398 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Authors: Tags: Scand J Work Environ Health Source Type: research
A higher risk for a variety of cancers is among the major complications of posttransplantation immunosuppression. In this part of a continuing series on cancers posttransplantation, this review focuses on the hematologic cancers after solid organ transplantation. Posttransplantation lymphoproliferative disorders (PTLDs), which comprise the great majority of hematologic cancers, represent a spectrum of conditions that include, but are not limited to, the Hodgkin and non‐Hodgkin lymphomas. The oncogenic Epstein‐Barr virus is a key pathogenic driver in many PTLD cases, through known and unknown mechanisms. The other hemat...
Source: American Journal of Transplantation - Category: Transplant Surgery Authors: Tags: COMPREHENSIVE REVIEW Source Type: research
This study focuses on the efficacy of pegfilgrastim in PBSC mobilization compared to filgrastim exclusively after novel agent-based induction in a homogeneous group of MM patients. We analyzed 89 patients with MM treated at two transplant centers in Singapore who received novel agent-based induction chemotherapy, PBSC mobilization with vinorelbine / cyclophosphamide, high-dose melphalan conditioning and autologous stem cell rescue. 61 patients were included in the pegfilgrastim group and 28 in the filgrastim group, with a similar median age and disease characteristics. PBSC harvesting was done at a similar median time of 9...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion In a large database capturing a heterogeneous patient population and varied treatment patterns reflecting routine clinical care, we found a clinical benefit of continued longer DOT at first relapse. Despite the emerging paradigm favoring continuous therapy, second-line PFS (proxied by TTNT) was over 2-fold longer than DOT. Understanding barriers to extended duration of therapy may help improve outcomes in RRMM. Teaser Despite the emerging paradigm favoring continuous therapy, we report that in routine clinical care, myeloma patients at first relapse frequently discontinue treatment before progression, resulting ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 5 January 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Henry Chan, Madeline Phillips, Manjula Maganti, Sophia Farooki, Giovanni Piza Rodriguez, Esther Masih-Khan, Christine Chen, Anca Prica, Donna Reece, Rodger Tiedemann, Suzanne Trudel, Vishal Kukreti
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion In patients with RRMM who are suitable for an IMiD-containing regimen, DRd has clear advantages in survival and response outcomes over other IMiD-containing regimens. Teaser A systematic review and network meta-analysis were conducted to compare the clinical efficacy of immunomodulatory drug–containing regimens in patients with RRMM. Daratumumab plus lenalidomide and dexamethasone had a significant advantage in improving progression-free survival in patients compared to other immunomodulatory-containing regimens.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Multiple myeloma (MM) is a malignant plasma cell condition with variable long-term outcomes. Depending on the patients ’ risk factors, long-term overall survival can range from under 2 years to more than 10 years [1, 2]. One of the most important prognostic factors in this condition is disease cytogenetics, which are now commonly assessed using fluorescent in-situ hybridization (FISH) [1-3]. Amongst all of the cyt ogenetic abnormalities detected by FISH that are deemed as high-risk, translocation of the fibroblast growth factor receptor 3 (FGFR3) and multiple myeloma SET domain (MMSET) on chromosome 4 with the IgH ge...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Clinical Trials | Conferences | Databases & Libraries | Hematology | Leukemia | Lymphoma | Myeloma